-+ 0.00%
-+ 0.00%
-+ 0.00%

Vaxcyte publishes investor presentation highlighting broad-spectrum pneumococcal vaccine pipeline lead VAX-31

PUBT·06/02/2026 20:17:36
Listen to the news
Vaxcyte publishes investor presentation highlighting broad-spectrum pneumococcal vaccine pipeline lead VAX-31
  • Vaxcyte highlighted completed enrollment in OPUS-1, a Phase 3 noninferiority trial for VAX-31 in U.S. adults aged 50 and older.
  • Topline OPUS-1 safety, tolerability, immunogenicity data targeted for Q4 2026; OPUS-2 and OPUS-3 readouts targeted for H1 2027.
  • VAX-31 holds FDA Breakthrough Therapy designation for invasive pneumococcal disease, pneumonia; designed to cover about 95% of IPD in adults.
  • Cash, cash equivalents, investments totaled about $2.7 billion as of 3/31/26.
  • Manufacturing strategy includes a global commercial agreement with Lonza; separate Thermo Fisher deal for U.S. fill-finish capacity in North Carolina.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.